Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy.

Abstract

To evaluate the clinical safety of a taurine containing irrigation solution (AcriProTect) before its routine application in pars plana vitrectomy (PPV). Twenty-five patients who underwent PPV were included in this prospective interventional clinical study. Standard irrigation solution containing the addendum 3 mmol/L taurine was used during PPV. Postoperative follow-up visits included a standard eye examination, corneal thickness measurements, endothelial cell counts, determination of the foveal thickness by optical coherence tomography (OCT), and an electrophysiologic examination. For statistical analysis Wilcoxon test was used. Significant improvement of visual acuity (VA) was observed at the 3- and 6-month controls (P = 0.024; P = 0.002 for 3 and 6 months, respectively). Endothelial cell counts and corneal thickness at 3 and 6 months were not significantly different from preoperative values (P = 0.204; P = 0.126 for endothelial cell count and P = 0.475; P = 0.095 for corneal thickness at 3 and 6 months, respectively). Both scotopic and photopic Ganzfeld electroretinography and electro-oculography did not show significant changes during the follow-up. No increase in complication rate was detected. The investigation demonstrates a good biocompatibility of taurine-containing irrigation solution developed for vitrectomy in humans concomitant with habitually observed good functional outcome.